CN110075175A - A kind of composition preventing macular degeneration - Google Patents
A kind of composition preventing macular degeneration Download PDFInfo
- Publication number
- CN110075175A CN110075175A CN201910416352.8A CN201910416352A CN110075175A CN 110075175 A CN110075175 A CN 110075175A CN 201910416352 A CN201910416352 A CN 201910416352A CN 110075175 A CN110075175 A CN 110075175A
- Authority
- CN
- China
- Prior art keywords
- macular degeneration
- composition
- vitamin
- cape jasmine
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Insects & Arthropods (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Animal Husbandry (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention proposes a kind of compositions for preventing macular degeneration, it is calculated by mass percentage for 100%, including silkworm excrement 17.5-25%, cape jasmine 20-25%, trace element zinc 0.1-0.3%, vitamin C 1.5-3%, vitamin E 0.05-0.15% and auxiliary material 46.55-60.85%, the composition has good preventive effect for macular degeneration, and it can directly take orally, get rid of the high problem of current macular degeneration treatment difficulty, with good application value, it is convenient for large-scale promotion.
Description
Technical field
The present invention relates to biomedicine technical field more particularly to a kind of combinations for preventing macular degeneration
Object.
Background technique
Universal with social senilization's progress faster and network, the illness probability of macular degeneration disease improves year by year.
At present for effective treatment method of macular degeneration and few, either age-related macular degeneration or juvenile macula lutea change
Property, there is no determining drug treatment, the new therapeutic strategy of the line occurred in recent years be concentrated mainly on prevent it is photosensitive thin
The damage of born of the same parents and retinal pigment epithelium, such as drug therapy, laser therapy collect treatment, plasma exchange and stem cell and base
Because for the treatment of etc., but these methods are in the stage of fumbling.
Therefore how early detection and effectively carry out prevention and treatment be at present a problem urgently to be solved.
Summary of the invention
In view of this, the invention proposes a kind of prevention macular degenerations easy to use, easy to spread
Composition.
The technical scheme of the present invention is realized as follows: the present invention provides a kind of macular degenerations of preventing
Composition, including silkworm excrement, cape jasmine, trace element zinc, vitamin C, vitamin E and auxiliary material.
On the basis of above technical scheme, it is preferred that be by mass percentage 100% meter, including following component:
On the basis of above technical scheme, it is preferred that calculated according to mass percent for 100%, including following component:
On the basis of above technical scheme, it is preferred that the auxiliary material includes vegetable oil, gelatin and glycerol.
Still more preferably, it is 100% calculating, including following component according to mass percent:
On the basis of above technical scheme, it is preferred that the auxiliary material includes starch and dextrin.
On the basis of above technical scheme, it is preferred that calculated according to mass percent for 100%, including following component:
On the basis of above technical scheme, it is preferred that the trace element zinc is zinc lactate.
The present invention also provides the compositions of prevention macular degeneration to prepare macular degeneration oral medicine
Application in object.
The macular degeneration includes age-related macular degeneration and juvenile macular degeneration.
Effective treatment method for macular degeneration is simultaneously few, at present in modern medicine, there is no determining drug therapy
Method.In recent years, many scholars have done a large amount of further investigation to macular degeneration pathogenesis, discovery aging with
Metabolism disorder, dyshaemia, light damage and oxidative damage, inflammatory reaction and relevant molecular genetics change etc., with view
The morbidity of nethike embrane macular degeneration disease is related.
Silkworm excrement alias original silkworm dung, horse ring liver, late silkworm excrement, Faeces bombycis, late silkworm excrement, two silkworm excrements, sweet in flavor, Xin Xingwen have and dispel
The effect of wind dehumidifying, promoting blood circulation analgesic therapy, stomach function regulating dampness elimination, mainly include phyllins, as pheophytin, 10- hydroxyl are de-
Magnesium pheophytin etc. has the effects that anti-inflammatory, anticancer, anti-light quick.
Cape jasmine alias Yellow Fructus Gardeniae, mountain Cape jasmine, gardenia florida, fructus garedeniae, bright red Cape jasmine, yellow chicken, more peach, Mu Dan, stand, branch,
Fructus gardeniae has effects that purging intense heat relieving restlessness, clearing heat and promoting diuresis, removing pattogenic heat from the blood and toxic material from the body, is used for Vexed, jaundice with damp-heat pathogen, the puckery pain of stranguria, blood
Hot hematemesis, red eye, swell pain, pathogenic fire,toxin and furuncles.
Cape jasmine contains different Gardenoside, geniposide, cape jasmine ketoside, shanzhiside, Geniposidic acid and flavonoids cape jasmine
Plain, triterpene compound crocin and crocetin, ursolic acid etc., modern pharmacological research, to the GOT of ligation ductus choledochus animal
Raising has apparent reduction to act on, and there are also choleretic effects, increase choleresis, and advantageous pancreas and the effect of drop pancreatin, decompression are made
With, sedation, bacteriostasis.
The composition of prevention macular degeneration of the invention has the advantages that compared with the existing technology
(1) Chinese medicine Lee theoretical basis and modern medicines research achievement are used, what is proposed under the guidance of theory of traditional Chinese medical science is completely new
Therapeutic scheme, overcome the high drawback of locally injecting Operative risk, using oral method, facilitate the daily treatment of patient；
(2) according to theory of traditional Chinese medical science and principle of medication, overcome the side effect of Western medicine and chemicals, the change in silkworm excrement and cape jasmine
Study point damage and reparation that effectively prevent photosensory cell and retinal pigment epithelium.
Specific embodiment
Below in conjunction with embodiment of the present invention, the technical solution in embodiment of the present invention is carried out clearly and completely
Description, it is clear that described embodiment is only some embodiments of the invention, rather than whole embodiments.Base
Embodiment in the present invention, it is obtained by those of ordinary skill in the art without making creative efforts all
Other embodiments shall fall within the protection scope of the present invention.
Embodiment 1
The composition for preventing macular degeneration includes: silkworm excrement 15g, cape jasmine 15g, zinc lactate 0.1g, vitamin
C1g, vitamin E 0.01g, vegetable oil 25g, gelatin 10g, glycerol 5g.
Preparation method: silkworm excrement effective component is extracted using alcohol-ammonium double-aqueous phase system, is extracted using alcohol-ammonium double-aqueous phase system
Cape jasmine effective component mixes silkworm excrement effective component, cape jasmine effective component with trace element zinc, vitamin C, vitamin E
Concentration, then the composition that concentrate is mixed to get prevention macular degeneration with vegetable oil, gelatin and glycerol will be mixed.
Embodiment 2
The composition for preventing macular degeneration includes: silkworm excrement 30g, cape jasmine 30g, zinc lactate 0.5g, vitamin
C5g, vitamin E 0.2g, vegetable oil 35g, gelatin 20g, glycerol 15g.
Preparation method: silkworm excrement effective component is extracted using alcohol-ammonium double-aqueous phase system, is extracted using alcohol-ammonium double-aqueous phase system
Cape jasmine effective component mixes silkworm excrement effective component, cape jasmine effective component with trace element zinc, vitamin C, vitamin E
Concentration, then the composition that concentrate is mixed to get prevention macular degeneration with vegetable oil, gelatin and glycerol will be mixed.
Embodiment 3
The composition for preventing macular degeneration includes: silkworm excrement 17.5g, cape jasmine 20g, zinc lactate 0.1g, dimension life
Plain C1.5g, vitamin E 0.05g, vegetable oil 29.21g, gelatin 12g, glycerol 5.34g.
Preparation method: silkworm excrement effective component is extracted using alcohol-ammonium double-aqueous phase system, is extracted using alcohol-ammonium double-aqueous phase system
Cape jasmine effective component mixes silkworm excrement effective component, cape jasmine effective component with trace element zinc, vitamin C, vitamin E
Concentration, then the composition that concentrate is mixed to get prevention macular degeneration with vegetable oil, gelatin and glycerol will be mixed.
Embodiment 4
The composition for preventing macular degeneration includes: silkworm excrement 25g, cape jasmine 25g, zinc lactate 0.3g, vitamin
C3g, vitamin E 0.15g, vegetable oil 38.21g, gelatin 15.64g, glycerol 7g.
Preparation method: silkworm excrement effective component is extracted using alcohol-ammonium double-aqueous phase system, is extracted using alcohol-ammonium double-aqueous phase system
Cape jasmine effective component mixes silkworm excrement effective component, cape jasmine effective component with trace element zinc, vitamin C, vitamin E
Concentration, then the composition that concentrate is mixed to get prevention macular degeneration with vegetable oil, gelatin and glycerol will be mixed.
Embodiment 5
The composition for preventing macular degeneration includes: silkworm excrement 17.5g, cape jasmine 20g, zinc lactate 0.1g, dimension life
Plain C1.5g, vitamin E 0.05g, starch 27.93g, dextrin 15.62g.
Preparation method: silkworm excrement effective component is extracted using alcohol-ammonium double-aqueous phase system, is extracted using alcohol-ammonium double-aqueous phase system
Silkworm excrement effective component and cape jasmine effective component are concentrated cape jasmine effective component, then by the silkworm excrement effective component after concentration, Cape jasmine
Sub- effective component, trace element zinc, vitamin C, vitamin E, starch and dextrin mixing, vacuum drying, granulation, tabletting obtain it is pre-
The composition of anti-macular degeneration.
Embodiment 6
The composition for preventing macular degeneration includes: silkworm excrement 25g, cape jasmine 25g, zinc lactate 0.3g, vitamin
C3g, vitamin E 0.15g, starch 36.51g, dextrin 24.34g.
Preparation method: silkworm excrement effective component is extracted using alcohol-ammonium double-aqueous phase system, is extracted using alcohol-ammonium double-aqueous phase system
Silkworm excrement effective component and cape jasmine effective component are concentrated cape jasmine effective component, then by the silkworm excrement effective component after concentration, Cape jasmine
Sub- effective component, trace element zinc, vitamin C, vitamin E, starch and dextrin mixing, vacuum drying, granulation, tabletting obtain it is pre-
The composition of anti-macular degeneration.
The preparation of macular degeneration model
It takes weight in the cleaning grade healthy adult male SD rat seven of 130-160g, is individually positioned according to Hansson
In seven lighting box of Sykes method preparation, by the illumination average out to (1900 ± 100) at center to different directions in lighting box
Rat eye eyelid suture is kept rat eye normally opened, adapted to 5 hours in lighting box by lux.
Drug treatment
Seven rats are sent to dark surrounds, are administered after three days, the placebo of control group feeding isodose, daily feeding
Once, continuous feeding 15 days, feeding situation is as follows:
| Grouping | Control group | Experimental group 1 | Experimental group 2 | Experimental group 3 | Experimental group 4 | Experimental group 5 | Experimental group 6 |
| Feeding drug | Placebo | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 |
| Feeding amount (g/kgd) | 1 | 1 | 10 | 1 | 10 | 1 | 10 |
| Feeding number of days (d) | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
Testing index and testing result
Rat retina tissue is removed, detects its Pathomorphology, Electronic Speculum watches its retina structure situation, as a result
It is as follows:
Result above is it is found that composition provided by the present invention has certain recovery at rat retina pathological tissues
Opsonic action.
The foregoing is merely better embodiments of the invention, are not intended to limit the invention, all of the invention
Within spirit and principle, any modification, equivalent replacement, improvement and so on be should all be included in the protection scope of the present invention.
Claims (9)
1. a kind of composition for preventing macular degeneration, which is characterized in that the composition include silkworm excrement, cape jasmine,
Trace element zinc, vitamin C, vitamin E and auxiliary material.
2. the composition of prevention macular degeneration as described in claim 1, which is characterized in that by mass percentage
It is calculated for 100%, including following component:
3. the composition of prevention macular degeneration as described in claim 1, which is characterized in that the auxiliary material includes
Vegetable oil, gelatin and glycerol.
4. the composition of prevention macular degeneration as claimed in claim 3, which is characterized in that by mass percentage
It is calculated for 100%, including following component:
5. the composition of prevention macular degeneration as described in claim 1, which is characterized in that the auxiliary material includes
Starch and dextrin.
6. the composition of prevention macular degeneration as claimed in claim 5, which is characterized in that by mass percentage
It is calculated for 100%, including following component:
7. the composition of prevention macular degeneration as described in claim 1, which is characterized in that the microelement
Zinc is zinc lactate.
8. the composition of prevention macular degeneration described in claim 1 is preparing macular degeneration oral medicine
Application in object.
9. such as application as claimed in claim 8, which is characterized in that the macular degeneration is age-related macular degeneration
Or juvenile macular degeneration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910416352.8A CN110075175A (en) | 2019-05-16 | 2019-05-16 | A kind of composition preventing macular degeneration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910416352.8A CN110075175A (en) | 2019-05-16 | 2019-05-16 | A kind of composition preventing macular degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110075175A true CN110075175A (en) | 2019-08-02 |
Family
ID=67420749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910416352.8A Pending CN110075175A (en) | 2019-05-16 | 2019-05-16 | A kind of composition preventing macular degeneration |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110075175A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1535116A (en) * | 2001-03-23 | 2004-10-06 | ʿ | Nutritional supplement to treat macular degeneration |
-
2019
- 2019-05-16 CN CN201910416352.8A patent/CN110075175A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1535116A (en) * | 2001-03-23 | 2004-10-06 | ʿ | Nutritional supplement to treat macular degeneration |
Non-Patent Citations (2)
| Title |
|---|
| 尤新: "《尤新食品发酵论文选》", 31 January 2005, 中国轻工业出版社 * |
| 胡兴明等: "《蚕桑优质高产高效技术问答》", 30 September 2014, 湖北科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100417394C (en) | Application of plant extract for preparing medicine to cure bone absorption increment diseases and composition thereof | |
| Husen et al. | Screening for antihyperglycaemic activity in several local herbs of Malaysia | |
| AU2016210622A1 (en) | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | |
| CN105394748A (en) | Method and composition for nutritionally improving glucose control and insulin action | |
| CN106511924B (en) | For hair growth, the externally-applied medicinal composition for promoting hair tonic and preparation method thereof | |
| CN104000944B (en) | A kind of health products or pharmaceutical composition and its production and use with warming kidney to invigorate yang | |
| CN110075175A (en) | A kind of composition preventing macular degeneration | |
| CN110623998B (en) | Traditional Chinese medicine composition for diabetic peripheral neuropathy and application thereof | |
| CN102036675B (en) | Use of black soybean for treating ophthalmic diseases | |
| CN103599340B (en) | Pharmaceutical composition used for treating and preventing diabetes and eye complications thereof, and applications of the pharmaceutical composition | |
| CN112755168B (en) | Traditional Chinese medicine preparation for treating chronic gastritis caused by helicobacter pylori and preparation method and application thereof | |
| KR100543342B1 (en) | Herbal medicnes for treating damage of neuronal cells | |
| CN102327404A (en) | Traditional Chinese medicine preparation for treating male venereal diseases | |
| CN1331493C (en) | Chinese medicine for treating star-like cataract caused by viral keratitis and preparation method thereof | |
| Saidu et al. | Phytochemical screening and effects of Methanolic Extract of Azadiractha indica leaf in Alloxan induced diabetic rats. | |
| CN108904650A (en) | A kind of Shuanghuanglian oral liquid and preparation method thereof for preventing and treating infectious laryngotracheitis | |
| CN101406526A (en) | Compound scutellaria microemulsion formulation and preparation method thereof | |
| CN103690660B (en) | Traditional Chinese medicine composition for stopping alopecia and regenerating hair and preparation method thereof | |
| CN106166234A (en) | One treats cataractous Chinese medicine composition | |
| CN104189365B (en) | Treat the Chinese medicine composition and its preparation and preparation method of human body pain | |
| CN103816224A (en) | Chinese medicine preparation for treating acute and chronic rhinitis and improvement on preparation method thereof | |
| CN105327151A (en) | Traditional Chinese medicine composition used for treating impotence, prostatitis and climacteric syndrome | |
| CN102861001A (en) | Novel application of cinnamic aldehyde for treating gastritis | |
| CN103142956A (en) | Medicine for treating viral myocarditis | |
| IT201800007105A1 (en) | A DRUG TO TREAT GASTROELCOSIS AND ITS METHOD OF PREPARATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190802 |
|
| RJ01 | Rejection of invention patent application after publication |